Correvio Pharma Corp. - Ordinary Shares (Canada) (CORV) News

Correvio Pharma Corp. - Ordinary Shares (Canada) (CORV): $0.42

0.00 (0.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CORV News Items

CORV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CORV News From Around the Web

Below are the latest news stories about Correvio Pharma Corp that investors may wish to consider to help them evaluate CORV as an investment opportunity.

Correvio Obtains Final Order for Plan of Arrangement

VANCOUVER , May 21, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") pursuant to which ADVANZ PHARMA, through its wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), has agreed to acquire all of the issued and outstanding shares of Correvio for a total purchase price of approximately US$76 million , which includes the repayment of certain Correvio indebtedness, as described in Correvio's information circular dated April 16, 2020 . The Arrangem...

Yahoo | May 21, 2020

Correvio Announces Results from Annual General and Special Meeting of Securityholders

VANCOUVER , May 15, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced the results of voting on matters considered at its annual general and special meeting (the "Meeting") of Correvio shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") which took place in a virtual format earlier today. At the Meeting, Securityholders were asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA").

Yahoo | May 15, 2020

Will Correvio Pharma (CORV) Report Negative Q1 Earnings? What You Should Know

Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 6, 2020

Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA

VANCOUVER , May 6, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, released a report (the "Glass Lewis Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.

Yahoo | May 6, 2020

Correvio Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19

Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has postponed the reporting of its financial statements and management discussion and analysis (the "2020 Disclosure") in respect of the first quarter ended March 31, 2020 beyond the previous expected date of May 15, 2020. The Company now expects to release its 2020 Disclosure on or before June 29, 2020, subject to the Company ceasing to be a reporting issuer prior to the filing deadline as a result of the Proposed Arrangement (as defined below).

Yahoo | May 4, 2020

Leading Independent Proxy Advisory Firm ISS Recommends That Correvio Shareholders Vote for the Arrangement with ADVANZ PHARMA

Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, released a report (the "ISS Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.

Yahoo | May 1, 2020

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal?

Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:

Yahoo | April 21, 2020

Correvio Obtains Interim Order For Plan Of Arrangement

VANCOUVER , April 8, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced  that it has obtained an interim order from the Supreme Court of British Columbia (the "Court") authorizing the holding of an annual general and special meeting (the "Meeting") of the Securityholders (as defined below) and matters relating to the conduct of the Meeting. At the Meeting, shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") will be asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Co...

Yahoo | April 8, 2020

Correvio Pharma (CORV) Reports Q4 Loss, Misses Revenue Estimates

Correvio (CORV) delivered earnings and revenue surprises of 23.08% and -1.66%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | March 30, 2020

Correvio Reports Full Year 2019 Financial Results

Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for the full year ended December 31, 2019 and commented on recent accomplishments and plans.

Yahoo | March 30, 2020


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5196 seconds.